CALR and essential thrombocythemia: In that study, positive rates of CALR mutation were 71%, 56%, and 86% in ET, PMF, and post-ET myelofibrosis patients, respectively, and CALR mutations were associated with higher platelet counts, lower hemoglobin levels, and more extensive fibrosis progression.